Baricitinib for Pediatric Immune Thrombocytopenia
Author Information
Author(s): G. López de Hontanar Torres, J. Zubicaray, E. Sebastián, A. Hernández-Martín, J. Iriondo, J. Sevilla
Primary Institution: Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Hypothesis
Can baricitinib effectively treat chronic immune thrombocytopenia in pediatric patients?
Conclusion
Baricitinib was successfully used to treat a 16-year-old patient with chronic immune thrombocytopenia and alopecia areata, leading to increased platelet counts and improvement in her condition.
Supporting Evidence
- The patient had severe thrombocytopenia and was treated with baricitinib after conventional therapies failed.
- Platelet counts increased significantly after starting baricitinib treatment.
- The treatment was well tolerated with no significant adverse effects reported.
Takeaway
A 16-year-old girl with a blood condition got better after taking a medicine called baricitinib, which helped her body make more platelets and also improved her hair loss.
Methodology
The case report details the treatment of a single pediatric patient with chronic immune thrombocytopenia using baricitinib, including clinical evaluations and laboratory tests.
Potential Biases
Potential bias due to the lack of a control group and reliance on a single patient's outcomes.
Limitations
The findings are based on a single case report, which may not be generalizable to all pediatric patients with immune thrombocytopenia.
Participant Demographics
One 16-year-old female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website